Nurse's Death Linked to NHS-Approved Weight-Loss Drug Mounjaro

Susan McGowan's death marks the first UK fatality associated with tirzepatide, raising concerns about its safety amidst a government-backed trial.

Susan McGowan, a nurse from North Lanarkshire, died after taking two doses of Mounjaro, a weight-loss drug recently approved for NHS use.
Her death certificate cites multiple organ failure and septic shock, with tirzepatide listed as a contributing factor.
Mounjaro, known for significant weight loss results, is part of a class of drugs called GLP-1 receptor agonists, which include Wegovy and Ozempic.
The UK government has invested £279 million in a trial to assess Mounjaro's impact on obesity and productivity, involving up to 3,000 participants.
Experts stress the importance of continued safety monitoring, noting that while individual cases are concerning, the drug's benefits may outweigh the risks for many users.